Actively Recruiting
Frailty Syndrome in Daily Practice of Interventional Cardiology Ward
Led by Medical University of Silesia · Updated on 2023-04-12
1000
Participants Needed
1
Research Sites
554 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The impact of frailty on immediate and long term outcomes of invasive treatment of coronary artery disease is not fully characterized. The assessment of frailty may help physicians in the selection of best treatment option and in the timing and modality of the follow-up. The FRAilty syndrome in daily Practice of Interventional CArdiology ward (FRAPICA) study is designed with the aim to validate the use of the Fried frailty scale and instrumental activities of daily living scale (IADL) as prognostic tools in patients admitted to hospital for symptomatic coronary artery disease, either stable, unstable, or acute coronary syndrome (ACS). The FRAPICA study is a single center prospective study enrolling patients aged ≥65 years. The aims are (1) to describe Fried frailty scale and IADL scale distribution before hospital discharge and (2) to investigate the prognostic role of Fried frailty and IADL scores. The outcomes are: (1) results of invasive treatment, (2) its complications (periinterventional MI, contrast-induced nephropathy, blood loss), (3) three-year all-cause mortality, cardiovascular mortality, stroke, myocardial infarction, reintervention, heart failure, hospital readmission for any cause, and a composite of the above mentioned. Ancillary analyses will be focused on different clinical presentations, different tools to assess frailty and risk stratification. The FRAPICA program will fill critical gaps in the understanding of the relation between frailty, cardiovascular disease, interventional procedures and outcome. It will enable more personalized risk assessment and identification of new targets for interventions.
CONDITIONS
Official Title
Frailty Syndrome in Daily Practice of Interventional Cardiology Ward
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 65 years or older
- Diagnosed with symptomatic coronary artery disease including stable, unstable, NSTEMI, or STEMI
- Able to provide written, informed consent
You will not qualify if you...
- Lack of consent to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
II Dept. of Cardiology in Zabrze Medical University of Silesia
Zabrze, Upper Silesia, Poland, 41-800
Actively Recruiting
Research Team
A
Andrzej R Tomasik, M.D. Ph.D., FESC
CONTACT
E
Ewa Nowalany-Kozielska, Prof.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here